Shandong Buchang Pharmaceuticals Co Ltd
SSE:603858
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Shandong Buchang Pharmaceuticals Co Ltd
SSE:603858
|
17.8B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
965.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
594B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
242.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.7B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
152.2B USD |
Loading...
|
|
| UK |
|
GSK plc
XETRA:GS71
|
105.9B EUR |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Shandong Buchang Pharmaceuticals Co Ltd
Glance View
Shandong Buchang Pharmaceuticals Co Ltd, a stalwart in China's pharmaceutical industry, was founded with a traditional focus but a modern vision. The company thrives on its deep expertise in developing and manufacturing traditional Chinese medicine (TCM) products, capitalizing on the rich tapestry of Eastern medicinal practices. Its extensive portfolio spans cardiovascular, cerebrovascular, and neurological disorders, areas highly pertinent to China’s aging population. By seamlessly integrating modern scientific techniques with age-old herbal wisdom, Buchang positions itself uniquely in a market that appreciates both tradition and innovation. This dual focus allows the company to tap into the growing demand for health solutions that marry efficacy with cultural familiarity. Financially, Buchang Pharmaceuticals' revenue is primarily fueled by its established healthcare products, which are marketed extensively across China’s vast healthcare network. The company shrewdly invests in building dedicated sales channels, leveraging a combination of direct engagement with healthcare professionals and strategic partnerships with medical institutions. Their emphasis on R&D ensures a steady pipeline of products, aiming to break into new therapeutic areas and expand its market presence. Buchang’s strategy to blend traditional remedies with modern delivery forms not only bolsters its domestic sales but also paves the way for potential international expansion, as global interest in holistic and alternative health solutions continues to grow. This sophisticated operational model underscores Buchang's ability to adapt and prosper amid shifting healthcare paradigms.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Shandong Buchang Pharmaceuticals Co Ltd is 0%, which is above its 3-year median of -4.2%.
Over the last 3 years, Shandong Buchang Pharmaceuticals Co Ltd’s Net Margin has decreased from 8.2% to 0%. During this period, it reached a low of -13.7% on Sep 30, 2023 and a high of 8.2% on Aug 30, 2022.